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Biophysical methodologyThe present work describes the drug:membrane interactions and a drug delivery system of the novel potent AT1
blocker BV6. This designed analog has most of the pharmacological segments of losartan and an additional
biphenyltetrazole moiety resulting in increased lipophilicity. We found that BV6:membrane interactions lead
to compact bilayers that may in part explain its higher in vitro activity compared to losartan since such environ-
mentmay facilitate its approach to AT1 receptor. Its high docking score to AT1 receptor stems frommore hydro-
phobic interactions compared to losartan. X-ray powder diffraction (XRPD) and thermogravimetric analysis
(TGA) have shown that BV6 has a crystalline form that is not decomposed completely up to 600 °C. These prop-
erties are desirable for a drug molecule. BV6 can also be incorporated into a mesoporous silicate drug-delivery
matrix SBA-15. The properties of the obtained drug-delivery system have been inspected by XRD, 13C CP/MAS,
TGA and nitrogen sorption experiments.
© 2013 Published by Elsevier B.V.1. Introduction
Coronary heart disease is one of the leading causes of death in the
industrialized world. Hypertension is a risk factor for cardiovascular
disease (CV) and is associated with an increased incidence of stroke
and coronary heart disease. Other risk factors for CV include also
high cholesterol, diabetes and obesity. Although there have been
many advances in treatment over the past several decades, less than
a quarter of all hypertensive patients have their blood pressure ade-
quately controlled with available therapies. Early management of
cardiovascular risk factors is fundamental in preventing the develop-
ment of cardiovascular and renal disease [1,2].
The renin–angiotensin system (RAS) is known to play an important
role in the regulation of blood pressure and electrolyte balance. Inhibi-
tors of the RAS would be effective for the treatment of hypertension
and congestive heart failure. Although angiotensin-converting enzyme
(ACE) inhibitors are highly effective and their use has become well-
established for the treatment of hypertension and congestive heart+30 210 7274761.
386 147 60300.
om@chem.uoa.gr
sevier B.V.failure, they suffer from some side effects such as dry cough and
angioedema caused by the nonspeciﬁc action of ACE. On the other
hand, angiotensin II (AII) AT1 receptor blockers (ARBs) selectively in-
terfere with the RAS at the AII receptor level and are expected to be
more speciﬁc and effective agents than ACE inhibitors. The discovery
of potent and orally active non peptide AII antagonists such as losartan
and eprosartan has encouraged the development of a large number of
similar compounds. Among them, candesartan cilexetil, valsartan,
irbesartan, telmisartan and olmesartanmedoxomil have been launched
and were established as angiotensin receptor blockers (ARBs). Treat-
ment with an ARB was demonstrated to reduce CV events and heart
failure progression as well as to improve renal disease and prevent dia-
betes and this constitutes the importance of their development. Despite
the plethora of treatment options for themanagement of hypertension,
55.9% of patients do not have their BP under adequate control. In addi-
tion, there is ambiguity concerning the appropriate choice of therapy for
hypertensive patientswhomay presentwith coexisting conditions such
as diabetes. Therefore, an agent with multifunctional purposes would
offer an efﬁcacious way of managing hypertension and related compli-
cations. Azilsartan medoxomil is a newer-generation ARB with potent
antihypertensive effects. On 25 February 2011, the U.S. Food and Drug
Administration (FDA) approved azilsartan medoxomil for the treat-
ment of high blood pressure in adults [3–5].
1847G. Agelis et al. / Biochimica et Biophysica Acta 1828 (2013) 1846–1855The molecular basis of their antihypertensive action has been
interpreted by a two-step model. In the ﬁrst step they are incorporat-
ed into the bilayers through the lipid–water interface and secondly
laterally diffuse to reach the active site of the AT1 receptor in order
to exert their biological activity [6].
BV6 (4-butyl-Ν,Ν -bis{[2 -(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}
imidazolium bromide) is a synthetic rationally designed molecule that
exhibited higher activity than losartan (Fig. 1). Thismolecule comprises
three well known pharmacophore segments identical to losartan, in
particular the two biphenyltetrazole segments at the N-1 and N-3 of
the imidazole ring and the butyl alkyl chain. However, it lacks the chlo-
rine atom and hydroxymethyl group on the imidazole ring. Its higher
activity can be postulated to be attributed to: (a) the way it interacts
on the lipid bilayer as it is amore lipophilic entity; (b) the additional hy-
drophobic interactions that it can have at the active site of the receptor
(Fig. 2) [7]. Estimated value of LogP for BV6 byALOGPS 2.1 programwas
found to be 5.70 (for comparison reasons LogP of losartan was found to
be 4.50) [8]. LogP values for all commercial sartans are given in Table 1.
BV6 has the highest LogP value after telmisartan.Fig. 1. Chemical structures of BV6 and LThe cellular membranes are complex entities consisting of various
kinds of proteins and lipids as well as cholesterol. Phosphatidylcholines
(PCs) are the most abundant lipid species in sarcolemma cardiac
membranes [9]. The most frequently found among them are PCs with
oleic and linoleic chains, and further dipalmitoylphosphatidylcholine
(DPPC). Experimentally, hydrated DPPC lipids are preferred because
they spontaneously formmultilamellar bilayers in whichmesomorphic
changes occur in a convenient temperature range between 25 and
50 °C. Their dynamic and thermotropic properties have been extensive-
ly explored [10–12] and their partition coefﬁcient especially in the ﬂuid
state, resembles that of natural cardiac membranes [9]. Phosphatidyl
choline bilayers at low temperatures occur in the gel phase (Lβ′) and
at higher temperatures in the liquid-crystalline phase (Lα). The transi-
tion is accompanied by several structural changes in the lipidmolecules
aswell as systematic alteration in the bilayer geometry, for example the
trans:gauche isomerization taking place in the acyl conformation. The
average number of gauche conformers indicates the effective ﬂuidity,
which depends not only on the temperature, but also on perturbation
due to the presence of a drugmolecule intercalating between the lipids.α-dipalmitoylphosphatidylcholine.
Fig. 2. Hydrophobic interactions of A. BV6 and B. losartan in the active site of AT1 receptor.
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form microdomains that modulate the activity of the vicinity of pro-
teins and thus offer a new avenue in the membrane lipid therapy. A
representative example is the drug:membrane interactions of the
β2 agonists indacaterol and salmaterol which are characterized by
different pharmacological properties. It was found that the synergy
between the higher partitioning of indacaterol into the raft
microdomains and the faster membrane permeation of indacaterol
could explain the faster onset and longer duration of therapeutic ef-
fect of indacaterol. The higher ﬂuidizing effect of salmeterol on mem-
brane ﬂuidity may contribute to its lower intrinsic efﬁcacy compared
to indacaterol [13]. Other studies postulated that active drugs do
change the lateral pressure proﬁle in bilayers and hence, can affect
the behavior of membrane proteins [1–6,9–16]. As a consequence of
this, every bioactive molecule has its special ﬁngerprint when it inter-
acts with membrane bilayers [17].
In this context, our laboratory has initiated research activity to
study the effects of ARBs losartan, valsartan, olmesartan, CV-11974
and TCV-116 in membrane bilayers [18–21]. Thus, the signiﬁcant
amount of work performed on AT1 receptor blockers could also
serve for comparative studies and further elaborate on the role of
the drug in the cell membrane. In this study, the effects of the syn-
thetic BV6 molecule intercalated in DPPC membranes were investi-
gated and then were compared with the commercial ARB drugs.
An integrated approach using different complementary methodol-
ogies namely solid state 13C CP/MAS13C MAS NMR spectroscopy,Table 1
LogP values of BV6 and AT1 antagonists calculated
by ALOGPS 2.1 program [8].
Compounds LogP
BV6 5.70
Losartan 4.50
Candesartan 4.02
Irbesartan 4.51
Valsartan 3.68
Olmesartan 1.79
Azilsartan 4.50
Telmisartan 6.66
Tasosartan 3.07HR-NMR spectroscopy, Differential Scanning Calorimetry (DSC), and
Raman spectroscopy, have been applied. Brieﬂy, DSC provides valu-
able information on the thermal modiﬁcations that are caused by
the presence of drugs in the membrane [22]. Solid state NMR experi-
ments offer useful information about the dynamic changes that drugs
cause when they are incorporated in the lipid bilayers [22–25]. Typi-
cal observations are related with chemical shift or intensity changes
of various key atoms which are partitioning in the membrane. Chem-
ical shift changes are further associated with phase transition proper-
ties of the membrane bilayers. Moreover new peaks arise due to the
presence of the drug. Raman experiments provide complementary
structural information, for instance regarding the interdigitation ef-
fects of the molecules in lipid bilayers [26–28].
In the last part of themanuscriptwediscuss the solid (powder) form
of BV6, and the drug-delivery system prepared from BV6 and the
mesoporous silicate matrix SBA-15 [29]. The role of silicate-based
drug-delivery systems in the transport of drugs through cell mem-
branes has not been explored yet. Rather, the silicate-based drug-
delivery systems were studied either to improve the availability of the
drugs that are poorly soluble in physiological media or to enable con-
trolled release of drugs in the body [30]. Since BV6 itself is well soluble
in water-rich media, the main purpose of incorporating it into the
mesoporous silicate matrix would be to gain control over the rate of
the drug release (for example, to achieve prolonged release of the
drug) or to gain control over the location of the drug release. On the in-
ternal and external surfaces, mesoporous silicates possess a signiﬁcant
amount of free silanol groups, which can be functionalized [31]. The
attached functional groups can change physico-chemical properties of
the surface and can therefore lead to speciﬁc interactions of the phar-
maceutical system with the target environment or with the external
stimuli. Some examples of functionalized mesoporous silicates used as
matrices for site-speciﬁc or/and stimuli-responsive drug delivery in-
clude a polyamine-functionalized mesoporous silicate that releases
drug only in neutral medium and not in the acidic one [32], SBA-15
functionalized with carboxylic groups that allow release of drugs only
in acidic medium [33], and mesoporous silicate functionalized with
superparamagnetic Fe3O4 nanoparticles, because ofwhich the transport
of drug-delivery particles within a body could be directed by external
magnetic ﬁelds [34]. In this contribution we study only the possibility
of the incorporation of BV6 into themesoporous silicate SBA-15matrix.
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2.1. Drug:membrane interaction system
2.1.1. Differential Scanning Calorimetry
To prepare the samples for DSC experiments, appropriate amounts of
DPPC and BV6 diluted in chloroformwere mixed, dried under stream of
argon and then stored under high vacuum overnight. Distilled and de-
ionized water was added to the driedmixtures of DPPC–BV6 to produce
a 50% (w/w) mixture/water preparation. The samples were transferred
to stainless steel capsules obtained from Perkin-Elmer and sealed. Ther-
mal scanswere obtained on a Perkin-ElmerDSC-2 instrument (Norwalk,
CT). All sampleswere scanned from 10 to 60 °C at least three times until
identical thermal scans were obtained using a scanning rate of
2.5 °C/min. The temperature scale of the calorimeter was calibrated
using indium (Tm = 156.6 °C) and DPPC bilayers (Tm = 41.2 °C).
The following diagnostic parameters were used for the study of drug
tomembrane interactions: Tm (maximum position of the recorded heat
capacity), Tonset (the starting temperature of the phase transition) and
ΔTm1/2 (the full width at half maximum of the phase transition), and
the respective parameters concerning the pre-transition. An empty
pan for the base line and a sample containing double distilled water
were run for the temperature range of 10–60 °C as a reference for the
background. This background was subtracted from each thermal scan
of the samples. The area under the peak represents the enthalpy change
during the transition (ΔΗ). The mean values of ΔΗ of three identical
scans were tabulated. The drug concentration used for the different ex-
periments was x = 0.20 (20 mol% BV6).
2.1.2. Raman spectroscopy
Raman spectra were recorded with a Perkin-Elmer GX Fourier
Transform spectrometer (Shelton, CT). A diode pumped Nd:YAG laser
at 1064 nm (Norwalk, CT) was used as the excitation source. The
scattered radiation was collected at an angle of 180° with respect to
the incident beam. Spectra were recorded at a laser power of 400 mW
on sample with a resolution of 2 cm−1. To obtain a good signal-
to-noise ratio, 2500 scanswere coadded for each spectrum. The temper-
ature was controlled using the high-temperature cell (CAL 3300,
Ventacon Ltd., Winchester, UK). The intensity of a Raman band was ob-
served over a period of 15 min. Analysis of the spectra was carried out
using Spectrum Software Version No. 3.02.01 (Perkin-Elmer, Norwalk,
CT). Raman spectra of the examined samples were obtained in the fre-
quency region of 3500–400 cm−1 and in the temperature range of 25
to 50 °C. The following ratios as a function of temperature were used
for the study of drug tomembrane interactions: I1090/I1130.: This ratio al-
lows the direct comparison of the bilayer disorder–order characteristics
between bilayers preparations without or with drug incorporation
[26,27]. I2935/I2880: This ratio measures the effects originating from
changes both in interchain and intrachain order–disorder processes in
the bilayer acyl chains. I2850/I2880: This ratio describes the main change
occurring in the hydrocarbon-chain region of the lipids and corresponds
to intermolecular interactions among aliphatic chains.
2.1.3. High resolution liquid and solid state NMR
Thehigh-resolutionNMRspectrawere recorded on aVarian800 MHz
spectrometer at 25 °C. Spectra were obtained with 2 mg of sample
dissolved in 0.7 ml CD3OD (Sigma Aldrich, St. Louis, MO). Default param-
eters installed in the library of the spectrometer were used. The 1H and
13C chemical shift assignments were obtained in a standard way using
DQF-COSY, HSQC, and HMBC 2D experiments. Spectra were collected in
the phase sensitive mode using the pulse sequences in the Varian library
of pulse programs. Spectra allowed the unambiguous assignment of BV6.
The procedure to prepare the samples for 13C MAS and 13C CP/MAS
spectroscopy was identical to that applied for DSC samples. Brieﬂy,
distilled and deionized water was added to the dried binary mixtures
of DPPC/BV6 to produce a 50% (w/w) liposome dispersion. The sampleswere transferred to 3.2 mm zirconia rotors. 13C NMR spectra were
obtained at 150.80 MHz with a 600 MHz Varian spectrometer (Palo
Alto, CA). The spinning rate used was 5 kHz. The experimental temper-
atures were 25 °C, 35 °C, and 45 °C for 13C CP/MAS experiments and
45 °C for the 13C MAS measurement.
2.2. Drug-delivery systems
BV6 was incorporated into the mesoporous silicate SBA-15 matrix.
SBA-15 was synthesized according to Sayari et al. [35] using structure
directing agent Pluronic P123 (PEG–PPG–PEG block copolymer,
Aldrich) and tetraethyl orthosilicate (98% TEOS, Aldrich) as a silica
source. Drug-loading procedure started by dissolving 70 mg of BV6 in
1 g of dimethyl sulfoxide (DMSO). The solution was added dropwise
to ﬁne layer of calcined SBA-15, allowing the powder to soak up the
added drops. The obtained sample was then dried using a two step dry-
ing procedure combining drying at 313 K for 24 h in a ventilation dryer
followed by drying at 313 K for 24 h in a vacuum dryer. The obtained
composite was denoted as SBA-15/BV6.
2.2.1. X-ray powder diffraction (XRPD)
XRPD patterns of solid samples were recorded on a PANalytical
X'Pert PRO high-resolution diffractometer using CuKα1 radiation
(1.5406 Å) in the 2θ range between 5° and 35°, taking 100 s for a
step of 0.033°. For the SBA-15/BV6 composite XRPD pattern was
recorded also in the 2θ range between 0.5° and 5°.
2.2.2. Thermogravimetric analysis (TG)
Thermogravimetric analyses (TG) were carried out between 298 K
and 873 K with a heating rate of 20 K/min using Mettler Toledo
(Schwerzenbach, Switzerland) thermo-gravimetric analyzer model
TGA/DSC 1 under a constant gas ﬂow rate (oxygen, 50 mL/min). The
initial sample masses ranged between 3 and 5 mg.
2.2.3. Nitrogen adsorption–desorption measurement
Adsorption and desorption isotherms of nitrogen were measured
on a Micromeritics ASAP 2020 volumetric adsorption analyzer at
77 K. Before the sorption analysis, SBA-15 and SBA-15/BV6 samples
were outgassed under vacuum for 4 h at 373 K. The BET speciﬁc sur-
face areas (SBET) were estimated using adsorption data in the relative
pressure range between 0.05 and 0.22 for SBA-15 and between 0.03
and 0.24 for SBA-15/BV6. The total pore volumes (Vt) for the empty
matrix and for the drug-delivery system were estimated from the
amounts of nitrogen adsorbed at relative pressures of 0.953 and
0.943, respectively, converting them to the volumes of liquid nitrogen
at 77 K. The microporosity (Vmi) was determined by the t-plot method.
The pore size distribution was obtained by analyzing the adsorption
data of the sorption isotherm using the DFT approach.
2.2.4. 13C CP/MAS NMR spectroscopy
13C CP/MAS NMR spectra were recorded on a 600 MHz Varian NMR
Systemequippedwith a 3.2 mmVarianMASprobehead. Larmor frequen-
cy for 13C nuclei was 150.812 MHz, relaxation delay was 5 s, CP contact
time was 5 ms, and sample rotation frequency was 16 kHz. Chemical
shift was reported relative to the signal of 13C nuclei in tetramethylsilane.
3. Results
3.1. Drug:membrane interactions
3.1.1. Differential Scanning Calorimetry
In previous studies we used Differential Scanning Calorimetry to
detect the thermal changes caused by AT1 receptor blockers when
they were incorporated in the lipid bilayers. We found out that x =
0.20 was the most critical to detect differential effects. For this reason,
we have chosen this concentration as a representative for comparison
25 30
DPPC
DPPC bilayers
bilayers+BV6
35 40 45 50 55
Temperature (oC)
m
Ca
l±±
s-
1
Fig. 3. Differential Scanning Calorimetry scans of DPPC bilayers alone (bottom) and
DPPC bilayers containing x = 0.20 of BV6 (top).
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shown in Fig. 3 revealed that BV6 causes enhancing of the bilayer
packing shifting the Tm from 42.2 °C to the higher value of 43.81 °C
(the corresponding Tonset for the bilayer with and without BV6 were
42.49 °C and 40.91 °C) and caused increase in ΔΗ (7.98 kcal/mol ver-
sus 6.95 kcal/mol observed for the lipid bilayers alone). BV6 caused
abolishment of the pre-transition temperature.25 30 35 40 45 50
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Fig. 4. Raman intensity ratios vs. temperature plots for pure DPPC (squares) and DPPC
containing x=0.20 of BV6 (circles).3.1.2. Raman spectroscopy
The methylene C\H stretching mode region 2800–3100 cm−1
provides the most intense bands in the Raman spectrum of lipid sam-
ples and is commonly used to monitor changes in the lateral packing
properties and mobility of the lipid chain in both gel and liquid crys-
talline bilayer systems. In particular, the intensity ratio I2850/I2880 pro-
vides an order parameter of the bilayer core. Indeed, this ratio
indicates that bilayers with incorporated BV6 are more ordered than
pure DPPC bilayers in accordance with DSC data (see Fig. 4A).
The C\C stretching mode region in the 1050–1150 cm−1 spectral
interval reﬂects directly intramolecular trans:gauche conformational
changes within the hydrocarbon chain region of the lipid matrix.
More importantly, the temperature proﬁles of the peak height intensity
ratio I1090/1130 allows the direct comparison of the bilayer disorder–
order characteristics between bilayer preparations without or with
BV6. BV6 induces lowering of gauche:trans ratio (see Fig. 4B).
The peak height intensity I2935/I2880 ratio constitutes a sensitive
probe to monitor the lipid phase transitions despite the fact that the
C\H stretching mode region consists of many superimposed vibra-
tional transitions. Fig. 4C shows changes in I2935/I2880 peak height in-
tensity ratio caused by BV6, when incorporated in DPPC bilayers.
DPPC bilayers alone and those containing BV6 resemble the corre-
sponding ones of the ratio I1090/I1130.
Various other bands are examined (not shown). For example the band
at 714 cm−1 is shifted to 717 cm−1 showing strong interaction of BV6
withpolar region. Bands corresponding to\CH3or\CH2werenot signif-
icantly affected. The bands at 1600 cm−1 and 1620 cm−1 which corre-
spond to the asymmetric and symmetric stretch vibrations of the C_C
bonds clearly conﬁrm the incorporation of BV6 in the lipid bilayers.3.1.3. 13C MAS and CP/MAS NMR spectroscopy
We have applied high-resolution NMR spectroscopy using magic
angle spinning without or with cross polarization to obtain detailed
local information on the incorporation of BV6 in the DPPC bilayers.Each spectrum was divided into three regions, namely concerning
the carbon atoms in the (i) hydrophobic region (10–40 ppm), those
in (ii) head-group, glycerol backbone regions and region containing
carbons between aromatic segments (55–80 ppm) and (iii) aromatic
and esteriﬁed carbonyls (125–180 ppm) (see Fig. 5).
T = 45oC
T = 35oC
T = 25oC
ppm
DPPC
DPPC+ BV6
DPPC
DPPC+ BV6
DPPC
DPPC+ BV6
35 30 25 20 1570 65 60 55170 160 150 140 130
Fig. 5. 13C NMR CP/MAS spectra of DPPC bilayers with and without BV6 at three temperatures covering all the mesomorphic states of the lipid bilayers.
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when DPPC bilayers undergo the transition from the lamellar gel phase
Lβ′ (25 °C) towards the ripple phase Pβ′ (35 °C) and lamellar liquid crys-
talline phase Lα (45 °C) (see Table 2 and Fig. 6). This is due to the strong
trans:gauche isomerization effects observed especially in the turnover to
the Lα phase. For example, we detected an upﬁeld change between 0.2
and 2.2 ppm for (CH2)′10, C-14′, C-15′ and C-16′ signifying the same
trend and different extent of upﬁeld effect of the carbons that constitute
the hydrophobic region. Upﬁeld effect (0.1–2.3 ppm) was also observed
in DPPC/BV6 bilayers. Generally, at the same temperature the values for
samples containing BV6 were slightly higher.
A peak at ca 15 ppm was observed which is attributed to the ter-
minal carbon of the methyl group (C9) of the butyl alkyl chain of BV6
as was elucidated using a combination of 1D and 2D NMR spectra (not
shown). Approximately at 25 ppm an eminent additional peak is
attributed to C8 of the alkyl chain. Several peaks of small intensityTable 2
Observed chemical shifts for DPPC carbons in 13C MAS and 13C CP/MAS experiments.
13C MAS
C-X
T
(°C)
Sample C-1 C-2 C-3 C-1′,
C-1″
C-2′,
C-2″
C-3′,
C-3″
(C
(C
DPPC 63.80 71.41 64.41 174.02 34.81 25.86 31
45 DPPC/BV6 63.90 71.53 64.54 174.15 34.86 25.79 31
13C /MAS
DPPC – 71.22 64.38 172−175 34.98 26.72 33
25 DPPC/BV6 – 71.54 64.71 173.95–175.55 – 26.77 33
DPPC – 71.14 64.38 172–175 35.10 26.37 33
35 DPPC/BV6 – 71.55 64.61 173.83–174.48 35.19 26.48 33
DPPC 63.77 71.37 64.49 174.03 34.81 25.85 31
45 DPPC/BV6 – 71.60 64.58 174.27 – 25.85 31
DPPC
DPPC+ BV6
70 65 60170    160 140 130150
Fig. 6. 13C NMR MAS spectra of DPPC bilahave been observed in the aromatic region. To examine the effect of
cross polarization we have run the same experiments at 45 °C using
MAS without applying cross polarization. Indeed all additional peaks
were also observed in MAS experiment (Fig. 6).
3.1.3.2. Head-group, glycerol backbone regions and region containing car-
bons between aromatic segments. Smaller chemical shift changes were ob-
served for the two preparations used in our experiments indicating that
head-group conformational changes from gel to liquid crystalline phase
are less pronounced compared to that observed in the hydrophobic re-
gion (Table 2). Speciﬁcally, a downﬁeld shift (b0.2 ppm) was observed
during the phase transition from the gel to liquid crystalline state for
the two preparations for the carbons of the head-group indicating, as is
already mentioned, its conformational stability in this bilayer region.
Steadily, as in the hydrophobic region the preparation containing BV6
had a slighter higher chemical shift than the pure DPPC bilayers.H2)′10,
H2)″10
C-14′,
C-14″
C-15′,
C-15″
C-16′,
C16″
N(CH3)3 C-2‴ C-1‴
.10 32.83 23.41 14.49 54.89 66.82 60.21
.09 (+3 shoulders) 32.91
33.12
23.48 14.58 54.95 66.91 60.32
.25 34.22 24.45 14.65 54.76 66.63 60.22
.35 – 24.26
+24.55
14.67 54.86 66.78 60.35
.11 – 24.25 14.60 54.79 66.69 60.20
.25 – 24.10
+24.39
14.65
+14.99
54.91 66.83 60.34
.06 32.79 23.39 14.49 54.86 66.81 60.19
.08+33.27 – 23.58 14.80 54.90 66.91 60.35
T = 45oC
ppm35 30 25 20 1555
yers with and without BV6 at 45 °C.
Fig. 7. XRPD patterns (A) and 13C CP/MAS NMR spectra (B) of the bulk substance BV6
and of the drug-delivery system SBA-15/BV6. Plot (B) contains tentative assignment of
13C CP/MAS NMR signals to carbon atoms within BV6. The numbers above the horizon-
tal lines correspond to carbon-atom labels as used in Fig. 1.
1852 G. Agelis et al. / Biochimica et Biophysica Acta 1828 (2013) 1846–1855An additional peak close to 55 ppm is observed which corre-
sponds to C10′ methylene group of BV6. This was also observed in
MAS experiments.
3.1.4. Aromatic and carbonyl regions
Only at 45 °C the aromatic region of BV6 is eminent but still con-
tains low intensity peaks. To test if this is due to inefﬁcient cross po-
larization we observed the corresponding MAS spectra. Clearly, in the
MAS spectra these peaks are still of low intensity signifying the fact
that their low intensity is attributed to rigidity of the bilayers when
BV6 is incorporated rather than inefﬁcient cross polarization.
The resolution of C-1′ in the carbonyl region for the two preparations
was not satisfactory to follow the chemical shift changes during the
phase transition. However, from the shape of the peaks it can be
realized that DPPC bilayers containing BV6 are more rigid compared
to the pure DPPC bilayers.
3.2. Analysis of the solid form and of the drug-delivery system
X-ray diffraction pattern of the powdered BV6 (Fig. 7A) exhibits
sharp diffraction peaks and shows that the neutral substance is a crystal-
line material. The 13C CP/MAS NMR spectrum (Fig. 7B) also exhibits rel-
atively narrow lines, which, however, overlap substantially so that the
contributions from the various carbon sites cannot be easily resolved.
(A tentative assignment of the resonances is presented in Fig. 7B.) Car-
bon signals resonating at about 160 ppm can be assigned to carbon
atomsof the tetrazole rings of BV6. It seems that the packing of BV6mol-
ecules within the crystals is such that either the two carbon sites within
the two tetrazole rings of the same molecule experience slightly differ-
ent environments or that two (crystallographically inequivalent) BV6
molecules comprise the crystallographic asymmetric unit.
The diffraction pattern of the drug-delivery system obtained after
the incorporation of BV6 into the mesopores of SBA-15 exhibits dif-
fraction peaks only in the range between 0.5° and 2°. These peaks
are characteristic for the ordered hexagonal arrangement of the
mesopores of the silicate matrix [29]. Obviously, the BV6 molecules
are too large and the pores of SBA-15 with the diameter of approxi-
mately 11 nm are too narrow that (sufﬁciently large) crystallites,
which would give rise to narrow diffraction maxima at higher diffrac-
tion angles, could be formed. As opposed to the diffraction maxima,
the signals within the 13C CP/MAS NMR spectrum of BV6 within the
delivery system are still clearly visible and only slightly broader
from the signals of the bulk crystalline substance. A new narrow sig-
nal at about 40 ppm belongs to the trace of solvent. Apparently the
drying procedure leaves traces of DMSO molecules within the pores.
The spectra of the powdered BV6 and the BV6 incorporated within
SBA-15 both exhibit two resolved signals of the tetrazole carbon nu-
clei. Since the packing of the neutral BV6 molecules within the
pores of SBA-15 is most probably different from the packing of
these molecules within the pure crystals, the two slightly different
environments for carbon nuclei within the two tetrazole rings must
stem from the asymmetry of a BV6 molecule alone and do not belong
to carbon nuclei from two separate BV6 molecules.
The crystalline BV6 and the drug-delivery system based on the sub-
stance were submitted also to thermogravimetric analysis (Fig. 8).
Somewhat surprisingly, in the temperature range between 25 °C and
600 °C BV6 was not entirely decomposed. This is most probably due
to the fact that BV6 is actually a salt and salts typically exhibit very
highmelting points. For the drug-delivery system the loss ofmasswith-
in the above mentioned temperature interval was even smaller, which
is understandable, knowing that the silicate mesoporous matrix is
completely stable up to 600 °C [29] and that the observed mass
loss was only due to the (partial) removal of the drug from the pores
of the drug-delivery system. If the reduction of the mass of drug within
the delivery system is comparable to the reduction of the mass of drug
in the bulk form, then the initial mass fractionm(BV6)/m(SBA-15/BV6)can be estimated to be approximately 0.55. This fraction is quite high
and exceeds the one that was observed for the drug-delivery systems
in which indomethacin was incorporated into SBA-15 [36,37]. If, how-
ever, up to 600 °C all the drug is expelled from the pores of the matrix,
then the initial mass fractionm(BV6)/m(SBA-15/BV6) can be estimated
to be approximately 0.35.
Table 3
Speciﬁc surface areas and pore volumes of SBA-15 and SBA-15/BV6 samples.
Sample SBET (m2/g) Vt (cm3/g) Vmi (cm3/g)
SBA-15 662 0.90 0.07
SBA-15/BV6 197 0.33 0.02
Fig. 8. TG proﬁles of the bulk BV6 and of the drug-delivery system SBA-15/BV6.
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system, ﬁnally, SBA-15/BV6 and the parent SBA-15 material were
subjected to the nitrogen sorption analysis. This analysis is an important
approach for the inspection of the porosity of the materials. The
measured adsorption–desorption isotherms and the derived pore-size
distribution proﬁles are presented in Fig. 9 and the quantitative data on
the speciﬁc surface area and pore volume of the two materials are listed
in Table 3. In the ﬁgure we can see that both nitrogen adsorption–
desorption isotherms are of type IV sorption isotherms according to
the IUPAC classiﬁcation and exhibit well-deﬁned H1 hysteresis loops,
which are typical for SBA-15 silicates. The presence of H1 hysteresis
type conﬁrms that the parent material and the drug-delivery system
have open-ended cylindrical mesopores. One can also see that after
the impregnation of the mesoporous silicate matrix with the BV6 drug,
the pore volume and the speciﬁc surface area were reduced drastically
— to approximately one third of the initial value. This is an indication
that indeed a substantial amount of the drug was incorporated into the
pores of SBA-15.
4. Discussion
4.1. DSC
The incorporated BV6 in lipid bilayers exerts similarities and dif-
ferences in thermal effects when these are compared with those
exerted by the commercial AT1 receptor blockers. The similarities
are expressed in: (a) abolishment of the pre-transition; (b) increase
of the breadth of the phase transition and (c) increase of ΔΗ. Howev-
er, BV6 is the only active AT1 antagonist studied so far that causes also
increase in Tm probably due to the fact that augments hydrophobic
interactions when it is embedded in the lipid bilayers. This favoredFig. 9. Nitrogen sorption isotherms (A) and pore sizpacking of lipid bilayers when BV6 is intercalated may explain its
suitable ﬁt in the core of the lipid bilayers and easy approach at the
AT1 active site resulting in high in vitro activity.4.2. Raman spectroscopy
The decrease of the mobility and gauche:trans ratio observed in
the Raman spectroscopy is in agreement with DSC results which
show that BV6 strengthens the packing of the lipid bilayers. Also in
the ratio of I2935/I2880 a shift was observed in higher temperatures
in accordance with DSC results. The strong interactions observed for
BV6 with head-group were in accordance with DSC results where
an abolishment of pre-transition was observed. The direct incorpora-
tion of BV6 in lipid core was observed by detecting C_C vibration
stretches in the region of 1600–1620 cm−1. This is again in harmony
with DSC results which showed a differential thermal scan proﬁle of
the bilayer containing BV6 in comparison with DPPC bilayers without
the drug. The ratio I2850/I2880 is considered also to be diagnostic for in-
terdigitation effects. As with most of the commercial AT1 antagonists,
BV6 appears to cause interdigitation effects in accordance with DSC
data which showed increase of ΔΗ and Tm.4.3. Solid state 13C CP/MAS and 13C MAS
In our previous studies we have observed that intensities in the aro-
matic region depend on the rigidity of the system.When prototype AT1
receptor blocker was incorporated in DPPC bilayers we were able to
structurally elucidate all the peaks attributed to the aromatic region [6].
This was not observed, however, in the case of DPPC bilayers
containing olmesartan where the aromatic region is more extended
[19]. In the case of BV6, the aromatic region is even more extended
and this leads to even more rigid system. Makriyannis et al observed
an identical relationship between GPCR cannabinoid agonists that
act on the head-group vicinity as it is recently reported by using
solid state 2H NMR spectroscopy. More speciﬁcally, the more rigid
Δ8-tetrahydrocannabinol compared with CP-55940 (synthesized
by Pﬁzer) andWIN-55212-2 (discovered by the SterlingWinthrop re-
search team) increased to a greater degree the order parameter of the
bilayer core [38].e distributions (B) of SBA-15 and SBA-15/BV6.
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XRD and NMR analyses showed that the solid form of BV6 is crys-
talline. The substance probably shows crystalline structure because it
is a salt, in which the positive charge on the imidazole ring is neutral-
ized by the Br− anion. Of course, salts are usually substances that
crystallize easily.
BV6 could be incorporated into the mesopores of the mesoporous
silicate matrix SBA-15 with a high ﬁlling fraction. The incorporated
substance resembles amorphous materials. Taking into account that
the chemical shifts for the bulk substance and the substance embed-
ded within the mesopores are almost the same, BV6 molecules most
probably interact with the silicate walls very weakly. Of course, the
interaction, which eventually inﬂuences the drug-release rate, could
be altered by the functionalization of the mesoporous silicate matrix.
5. Conclusions
We have studied the drug:membrane interactions and drug-delivery
system of a novel synthetic AT1 antagonist BV6 that possesses higher in
vitro activity than prototype drug in sartan class losartan. Although it has
almost all pharmacophoric segments of losartan, the novel analog BV6 is
bulkier and more lipophilic. Its high lipophilicity in conjunction with
its amphiphilic properties constitutes the driving force for its intercala-
tion in the lipid bilayers and increase of their packing abilities. These
properties are observed also with commercial AT1 antagonists but to
a lesser extent. Since BV6 has these desirable properties in the lipid bi-
layers that may explain in part its diffusion ability to the AT1 receptor
and its favorable binding, we found it interesting to investigate its
physico-chemical and delivery properties in SBA-15 system. Its crystal-
line properties and especially high stability in decomposition are highly
desirable properties for a drug. Its size and shape allow its packing into
the delivery SBA-15 system with a relatively high efﬁciency.
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